Clinical Pharmacology of a New Antiplatelet Drug, KBT-3022. Results of Single Administration in Japanese Healthy Adults.

Japanese Journal of Clinical Pharmacology and Therapeutics - Japan
doi 10.3999/jscpt.21.157
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Related search

Absorption, Distribution and Excretion of a New Antiplatelet Drug, Ethyl 2-(4,5-Bis(4-Methoxyphenyl)thiazol-2-Yl)pyrrol-1-Ylacetate, (KBT-3022), After Single Oral Asministration in Mice.

Drug Metabolism and Pharmacokinetics
1994English

Protective Effect of KBT-3022, a New Cyclooxygenase Inhibitor, in Cerebral Hypoxia and Ischemia.

The Japanese Journal of Pharmacology
1995English

Anti-Thrombotic Activity of KBT-3022 in Experimental Models of Thrombosis.

The Japanese Journal of Pharmacology
1995English

Inhibitory Effects of the New Anti-Platelet Agent KBT-3022 and Its Metabolite on Rabbit Neutrophil Function in Vitro.

The Japanese Journal of Pharmacology
1996English

Clinical Pharmacology and Drug Regulation

British Journal of Clinical Pharmacology
Pharmacology
1999English

Clinical Pharmacology. Adverse Drug Interactions.

BMJ
1981English

4. Clinical Perspectives of New Antiplatelet Drugs

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2009English

Clinical Pharmacology of a New Antithrombotic Agent, Ticlo

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1978English

Single-Dose Pharmacokinetics of Ceftriaxone in Healthy Chinese Adults.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1985English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy